| Cavo, Michele |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 177 | Europe, Canada, US, RoW | Belantamab mafodotin | GlaxoSmithKline | Multiple Myeloma | 08/24 | 02/25 | | |
|
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
| Completed | 1/2 | 18 | Europe, US, RoW | ZN-d5, Study Drug | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group Alpha, Inc | Amyloidosis, AL Amyloidosis | 02/24 | 02/24 | | |
| Recruiting | 1/2 | 258 | Europe, US, RoW | Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148 | Sanofi | Plasma Cell Myeloma Refractory | 07/27 | 03/28 | | |
| Recruiting | 1 | 144 | Europe, Canada, US, RoW | Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone | GlaxoSmithKline | Multiple Myeloma | 11/24 | 06/25 | | |
|
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
| Recruiting | N/A | 1900 | Europe | Observation | Fondazione EMN Italy Onlus | Multiple Myeloma | 03/24 | 03/24 | | |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | N/A | 586 | Europe, Japan, US, RoW | isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib | Sanofi | Plasma Cell Myeloma | 02/26 | 02/26 | | |
| Nava, Stefano |
| Terminated | 3 | 409 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 09/24 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy |
|
|
| Recruiting | 2 | 464 | Europe, RoW | Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo | Chiesi Farmaceutici S.p.A. | Uncontrolled Asthma | 12/25 | 12/25 | | |
NCT04605757: Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study |
|
|
| Recruiting | N/A | 100 | Europe | Clinical, functional and radiological lung involvement evolution | Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi | SARS-COV-2 Pneumonia | 04/21 | 07/21 | | |
| Recruiting | N/A | 100 | Europe | Prone Position (PP) | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Azienda Unità Sanitaria Locale Reggio Emilia, Azienda Ospedaliera di Bolzano, Azienda Ospedaliero-Universitaria di Modena | Covid-19 Infection | 06/21 | 07/21 | | |
NCT04577937: Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis |
|
|
| Recruiting | N/A | 15 | Europe | LAM patients underwent PSG | dr. Stefano Nava | Lymphangioleiomyomatosis, Sleep Disorder, Sleep Apnea Syndromes, Hypopnea Syndrome | 07/21 | 11/21 | | |
| Recruiting | N/A | 500 | Europe | | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari | Nontuberculous Mycobacteria | 12/22 | 12/22 | | |
| Completed | N/A | 20 | Europe | AIRVO 2, with conventional symmetric nasal cannula, standard cannula, AIRVO 2, the new asymmetric nasal cannula, "Optiflow+ Duet" | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Chronic Obstructive Pulmonary Disease | 09/23 | 10/23 | | |
EAD-IPF-N, NCT06714812: Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib |
|
|
| Active, not recruiting | N/A | 100 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | IPF | 12/23 | 10/25 | | |
IPF-PPC, NCT06714188: Application of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis |
|
|
| Active, not recruiting | N/A | 30 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | IPF | 07/24 | 09/25 | | |
| Active, not recruiting | N/A | 130 | Europe | Over-night treatment with myAIRVO2 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione Salvatore Maugeri, Università degli Studi di Ferrara, Azienda Ospedaliero, Universitaria Pisana, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale San Paolo, Universita degli Studi di Catania, Azienda Ospedaliera di Padova, University of Palermo, Azienda Ospedaliero-Universitaria di Parma, University of Foggia, Monaldi Hospital, Fondazione Don Carlo Gnocchi Onlus, Ospedale San Donato | Bronchiectasis Adult | 01/25 | 01/25 | | |
FISIOBRONCHI, NCT06801327: Comparison Between Conventional Respiratory Physiotherapy and the Simeox Device in Patients With Bronchiectasis |
|
|
| Recruiting | N/A | 40 | Europe | Simeox | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bronchiectasis Adult | 09/25 | 03/26 | | |
RECAP, NCT06800586: Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects |
|
|
| Not yet recruiting | N/A | 300 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | COPD, Lung Cancer (NSCLC), Leukemia | 07/26 | 08/26 | | |
| Not yet recruiting | N/A | 284 | NA | ECCO2R, NIV | University of Bologna, University of Milan, University of Turin, Italy, University of Roma La Sapienza | Pulmonary Disease, Chronic Obstructive | 01/27 | 06/27 | | |
| Pinna, Antonio Daniele |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
NCT05045794: Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation |
|
|
| Completed | N/A | 219 | US | VitaSmart Liver Machine Perfusion System, VitaSmart Liver Machine, Hypothermic oxygenated perfusion, Static cold storage | Bridge to Life Ltd. | End Stage Liver DIsease, Liver Failure | 06/24 | 06/24 | | |
| VIANELLI, Nicola |
| Completed | 2 | 41 | Europe, Japan, US, RoW | Placebo, TAK-079 | Takeda | Primary Immune Thrombocytopenia | 04/24 | 04/24 | | |
| Recruiting | N/A | 861 | Europe | Observation | Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation | Idiopathic Thrombocytopenic Purpura | 07/23 | 07/23 | | |
NCT06466824: Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010 |
|
|
| Not yet recruiting | N/A | 157 | NA | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Primary Immune Thrombocytopenia | 03/25 | 03/25 | | |
| Recruiting | N/A | 200 | Europe | peripheral blood and bone marrow withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | Immune Thrombocytopenia | 11/26 | 11/26 | | |
| Pillastrini, Paolo |
NCT05399472: Teenage Functional Hallux Limitus and Ankle Dorsiflexion Study |
|
|
| Enrolling by invitation | N/A | 50 | Europe | Dorsiflexion lunge test, Jack Test | University of Bologna | Hallux Limitus, Ankle Joint | 06/22 | 07/22 | | |
NCT05636423: Sexual Disability in Low Back Pain and Physiotherapy |
|
|
| Completed | N/A | 502 | Europe | Survey | University of Bologna | Low Back Pain, Sex Disorder | 06/23 | 07/23 | | |
| Zinzani, Pier Luigi |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 170 | Europe, US | IPH4102, lacutamab | Innate Pharma | Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | 10/23 | 01/26 | | |
|
|
|
|
|
|
| Active, not recruiting | 2 | 82 | Europe, US, RoW | brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone | Seagen Inc. | Peripheral T-cell Lymphoma | 05/24 | 12/25 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
| Active, not recruiting | 2 | 28 | Europe | Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet | Niguarda Hospital | CLL Transformation | 09/26 | 12/26 | | |
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/27 | 11/29 | | |
| Recruiting | 1/2 | 60 | Europe, US | EO2463, lenalidomide, Revlimid, rituximab, MabThera | Enterome | Follicular Lymphoma, Marginal Zone Lymphoma | 05/26 | 05/32 | | |
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) |
|
|
| Recruiting | 1/2 | 160 | Europe, Canada, US, RoW | ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide | Allogene Therapeutics | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | 01/25 | 05/29 | | |
| Recruiting | 1/2 | 210 | Europe, US, RoW | CPI-0209 | Constellation Pharmaceuticals | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma | 12/25 | 03/26 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme |
|
|
| Active, not recruiting | N/A | 100 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | DLBCL - Diffuse Large B Cell Lymphoma | 12/25 | 12/25 | | |
| Recruiting | N/A | 1300 | Europe | COVID-19 vaccines | Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna | COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases | 07/21 | 04/22 | | |
| Recruiting | N/A | 5500 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Lymphoproliferative Syndrome, Autoimmune, Lymphoma | 12/27 | 12/27 | | |
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context |
|
|
| Recruiting | N/A | 50 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Primary Mediastinal B Cell Lymphoma | 12/25 | 12/25 | | |
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients |
|
|
| Active, not recruiting | N/A | 15 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Diffuse Large B Cell Lymphoma (DLBCL) | 12/25 | 12/25 | | |
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 200 | Europe | peripheral blood sampling | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hodgkin Lymphoma in Remission | 09/25 | 09/25 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma |
|
|
| Active, not recruiting | N/A | 50 | Europe | Gut microbiota samples | University of Bologna | Diffuse Large B Cell Lymphoma | 07/23 | 12/23 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life |
|
|
| Active, not recruiting | N/A | 170 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | DLBCL - Diffuse Large B Cell Lymphoma | 02/24 | 04/26 | | |
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. |
|
|
| Not yet recruiting | N/A | 125 | Europe | Zanubrutinib | Fondazione Italiana Linfomi - ETS | Waldenström's Macroglobulinemia (WM) | 07/26 | 07/26 | | |
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 40 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hodgkin Lymphoma | 02/27 | 02/27 | | |
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma. |
|
|
| Not yet recruiting | N/A | 125 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Non-Hodgkin Lymphoma | 12/26 | 12/26 | | |
| Not yet recruiting | N/A | 400 | Europe | | Fondazione Italiana Linfomi - ETS, Takeda | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 07/26 | 07/26 | | |
| Recruiting | N/A | 45 | Europe | Peripheral and BM blood sample | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hairy Cell Leukemia | 11/25 | 11/25 | | |
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 05/25 | 07/25 | | |
| Recruiting | N/A | 160 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Marginal Zone B Cell Lymphoma | 10/25 | 10/25 | | |
| Recruiting | N/A | 1000 | US | | University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA) | Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant | 09/26 | 09/26 | | |
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy |
|
|
| Recruiting | N/A | 90 | Europe | Gut microbiome analysis | University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna | Diffuse Large B Cell Lymphoma | 07/27 | 12/27 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
| Bugiardini, Raffaele |
| Enrolling by invitation | N/A | 130000 | Europe | Non-interventional patient registry | University of Bologna | Acute Coronary Syndrome, Unstable Angina Pectoris, Myocardial Infarction, Coronary Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 36000 | Europe | | University of Bologna | Acute Coronary Syndrome, Unstable Angina Pectoris, Myocardial Infarction, Coronary Disease | 12/26 | 12/26 | | |
| Pinto, Antonio |
| Completed | 3 | 500 | Europe | Doxorubicin, Bleomycin, Vinblastine, Dacarbazine | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/21 | 11/24 | | |
FIL-RougeBIO, NCT05066555: Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial |
|
|
| Completed | 3 | 100 | Europe | | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/21 | 11/24 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Terminated | 2 | 22 | Europe | ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147 | Lung Cancer Group Cologne | Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV | 09/22 | 10/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 2 | 244 | Europe, Canada, US, RoW | Selinexor, KPT-330 | Karyopharm Therapeutics Inc | Diffuse Large B-cell Lymphoma | 04/27 | 11/27 | | |
|
|
|
|
|
|
|
|
|
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/27 | 11/29 | | |
| Recruiting | 1/2 | 60 | Europe, US | EO2463, lenalidomide, Revlimid, rituximab, MabThera | Enterome | Follicular Lymphoma, Marginal Zone Lymphoma | 05/26 | 05/32 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
NCT06600568: Novel Therapeutic Approach for Human T-cell Malignancies |
|
|
| Recruiting | N/A | 120 | Europe | Translation analysis | Istituto Oncologico Veneto IRCCS, Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale | T-Cell Leukemia/Lymphoma, Adult | 07/26 | 07/26 | | |
| Borghi, Claudio |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06398522: Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome |
|
|
| Completed | N/A | 50 | Europe | Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3, Placebo | University of Bologna | NAFLD, Metabolic Syndrome | 06/18 | 06/18 | | |
| Completed | N/A | 60 | Europe | Coenzyme Q10, Placebo | University of Bologna | Hypercholesterolemia, Physical Performance | 03/19 | 03/19 | | |
NCT04485793: Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia |
|
|
| Completed | N/A | 50 | Europe | Dietary supplement, Placebo | University of Bologna | Hypercholesterolemia | 10/21 | 10/21 | | |
NCT06247137: Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation |
|
|
| Completed | N/A | 90 | Europe | Dietary Supplement, Placebo | University of Bologna | Hypercholesterolemia | 12/22 | 12/22 | | |
Youcare, NCT05771142: Evaluation of an Innovative Smart T-shirt Capable to Monitor ECG Signal and Related Parameters Through the Comparison With a Holter ECG and a Smartwatch |
|
|
| Recruiting | N/A | 30 | Europe | Smart t-shirt, ECG Holter, Smartwatch | University of Bologna, AccYouRate S.p.A. | Cardiac Arrhythmias | 05/23 | 05/23 | | |
| Recruiting | N/A | 10000 | Europe | | Heart Care Foundation | Heart Failure | 06/26 | 07/26 | | |
NUT1-BO-2022, NCT06403748: Effect of a Dietary Supplement on Lipid Pattern, Indexes of NAFLD and Systemic Inflammation in Healthy Subjects With Suboptimal LDL-C Levels |
|
|
| Not yet recruiting | N/A | 90 | Europe | Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients., Placebo | University of Bologna | Hypercholesterolemia, Inflammation | 10/24 | 10/24 | | |
EDIPE, NCT05999851: Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy |
|
|
| Not yet recruiting | N/A | 400 | Europe | Arterial applanation tonometry, PulsePen, Arterial stiffness measurement, Pulse wave velocity assessment, In vivo endothelial glycocalyx measurement, Glycocheck, Sidestream dark field microscopy, Serum markers of angiogenesis and endothelial dysfunction, ANG-1, ET-1, ICAM-1, VCAM-1, ANG-2, Blood chemistry test, Serum xanthine oxidase activity | IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna | Preeclampsia, Hypertensive Disorder of Pregnancy | 05/26 | 09/31 | | |
| Morgia, Chiara La |
ACON, NCT05605951: Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve |
|
|
| Recruiting | N/A | 200 | Europe, Japan, US, RoW | non-interventional study | Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul | Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Optic Neuritis | 12/25 | 12/25 | | |
| Palandri, Francesca |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
|
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients |
|
|
| Active, not recruiting | 3 | 117 | Europe, RoW | Ropeginterferon alfa-2b (BESREMi®) | AOP Orphan Pharmaceuticals AG | Essential Thrombocythaemia | 03/28 | 03/28 | | |
| Recruiting | 3 | 350 | Europe, Canada, US, RoW | Selinexor, KPT-330, Placebo, Ruxolitinib | Karyopharm Therapeutics Inc | Myelofibrosis | 09/25 | 03/28 | | |
|
|
|
|
|
|
| Active, not recruiting | 2 | 21 | Europe, US, RoW | GB2064 | Galecto Biotech AB, OPIS s.r.l | Myelofibrosis | 12/23 | 06/26 | | |
| Recruiting | 2 | 230 | Europe | RVU120, SEL120, Ruxolitinib, RUX | Ryvu Therapeutics SA | Myelofibrosis | 06/26 | 10/27 | | |
